Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Diffuse Large B-Cell Lymphoma

Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Mantle Cell Lymphoma: Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Mantle Cell Lymphoma

Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Follicular Lymphoma: Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Follicular Lymphoma

Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Primary Mediastinal B-Cell Lymphoma

Data Insights

P-CD19CD20-ALLO1 by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval

P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Marginal Zone B-cell Lymphoma